PRAX250516P65000
- 20.30
- 0.000.00%
Praxis Precision Medicines Newsroom
Praxis Precision Medicines Shares Promising EMBOLD Study Data
Press Release: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines GAAP EPS of -$3.29
Praxis Precision Medicines Reports Significant Progress and Upcoming Milestones in Epilepsy Portfolio
Praxis Precision Medicines | 10-Q: Q1 2025 Earnings Report
Praxis Precision Medicines | 8-K: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
Praxis Precision Med 1Q Loss/Shr $3.29 >PRAX
Praxis Precision Med 1Q Research and Development Expenses $60.8M >PRAX
Express News | Praxis Precision Medicines Inc - Maintains Runway Into 2028
Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
Express News | Praxis Precision Q1 EPS USD -3.29 Vs. IBES Estimate USD -3.2
Express News | Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
Express News | Praxis Precision Q1 Operating Income USD -74.728 Million Vs. IBES Estimate USD -67.8 Million
Express News | Praxis Precision Q1 Net Income USD -69.296 Million Vs. IBES Estimate USD -64.3 Million
Express News | Praxis Precision Q1 Operating Expenses USD 74.728 Million
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $105
Praxis Precision Med Price Target Maintained With a $105.00/Share by HC Wainwright & Co.
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $85
EMERGN INTRODUCES PRAXIS BUSINESS & ENTERPRISE: THE GOLD STANDARD FOR PRODUCT MANAGEMENT EXCELLENCE